HIGHLIGHTS
- who: V. Polito from the (UNIVERSITY) have published the research work: Type I allergic reaction to rituximab upon first lifetime exposure: a case report, in the Journal: (JOURNAL)
SUMMARY
Rituximab is a chimeric monoclonal antibody (MAB), which is approximately 65% human, the remainder being mouse epitope. On day 2 post-rituximab, she also developed 1 day of throat pain. She was given famotidine 20 mg and methylprednisolone 80 mg intravenously (IV), and diphenhydramine 50 mg orally (PO). Cytokine-mediated reactions can present with similar symptoms, however unlike infusion reactions, they can persist many . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.